PTGDR2 and Miyoshi myopathy: To overcome this issue, we instead used the GATA-3 marker to assess ILC2 quantification, confirming the reduction in these cells in the BM but not in the PB of MM patients (Figure 1C) and highlighting that CRTH2 fails in identifying ILC2s in this context.